Livsayis (cemdisiran): FDA approval, pivotal trial and safety

Approved
Type
Oligonucleotide
FDA-approved use
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravisWording from FDA's list of novel approvals.

At a glance

Livsayis (cemdisiran) is a subcutaneous small interfering RNA that suppresses complement component 5 (C5). The FDA approved it to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In the phase 3 NIMBLE trial, the placebo-adjusted difference in MG-ADL change at week 24 was -2.3 points (95% CI -3.6 to -1.0; P=0.0005). No serious or meningococcal infections occurred in the cemdisiran group, and there is no boxed warning.

What it is and how it works

Cemdisiran is a GalNAc-conjugated siRNA that reduces liver production of C5. It acts upstream of the terminal complement cascade by lowering the amount of C5 protein, rather than blocking circulating C5 as the antibody inhibitors do. Pharmacodynamic data show a long duration of C5 suppression after dosing, which allows infrequent subcutaneous administration. Other targeted options for this disease lower overall antibody levels or inhibit complement activity.

Pivotal trials

NIMBLE NCT05070858

Design
Phase 3, randomized, double-blind, placebo-controlled trial at 86 centers in 13 countries. The treatment period was 24 weeks. Arms were cemdisiran alone, pozelimab alone, cemdisiran plus pozelimab, and placebo, all given subcutaneously.
Patients
284 randomized adults with generalized myasthenia gravis, positive anti-AChR or anti-LRP4 serology, and an MG-ADL score of 6 or greater. The primary analysis set was the first 245 randomized patients who received treatment and had a post-baseline assessment (cemdisiran n=64, combination n=67, placebo n=59).
Compared with
Placebo. Pozelimab alone was not statistically tested against placebo.
Primary endpoint
Change from baseline in MG-ADL total score at week 24.

Result

Least-squares mean change was -4.5 with cemdisiran, -4.0 with the combination, and -2.2 with placebo. The placebo-adjusted difference was -2.3 with cemdisiran (95% CI -3.6 to -1.0; P=0.0005) and -1.7 with the combination (95% CI -3.0 to -0.4; P=0.0086).

Other results
Key secondary results are not given in the sources.
Safety in the trial
Any adverse event occurred in 69% with cemdisiran, 81% with the combination, 82% with pozelimab, and 77% with placebo. Upper respiratory tract infection was most common with cemdisiran (12%) versus 11% with placebo. No serious or meningococcal infections occurred with cemdisiran. Discontinuations for adverse events occurred in two placebo patients and one pozelimab patient. No deaths occurred in the double-blind period.

Source: Vu T, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407:1712-1725.

EvidencePulse™

Ask about Livsayis

The question that opens in EvidencePulse

How does Livsayis (cemdisiran) compare with the alternatives (Eculizumab, Ravulizumab, Efgartigimod) for anti-acetylcholine receptor antibody-positive generalized myasthenia gravis? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.

Ask in EvidencePulseFree to try, more with 2MM+.

Deep research is a core feature of 2MM Max.

Safety signals

There is no boxed warning. In NIMBLE, adverse events occurred in 69% of the cemdisiran group and 77% of the placebo group. Upper respiratory tract infection was the most common event with cemdisiran (12%) and occurred at a similar rate with placebo (11%). No serious or meningococcal infections occurred in the cemdisiran group, though C5 suppression as a class carries a theoretical infection risk that clinicians should keep in mind. No deaths occurred during the double-blind period. Two deaths occurred afterward, one of which the investigator, but not the sponsor, judged treatment-related. In a phase 2 IgA nephropathy trial, injection-site reaction was the most common event (41%).

What it competes with

Generalized myasthenia gravis is treated with symptomatic cholinesterase inhibitors and immunosuppression, including corticosteroids and steroid-sparing agents. Targeted biologics are used for patients with inadequate control.

  • EculizumabC5 antibody inhibitor given by intravenous infusion, with an established record in AChR antibody-positive disease.
  • RavulizumabLong-acting C5 antibody inhibitor given by intravenous infusion.
  • EfgartigimodNeonatal Fc receptor blocker that lowers IgG autoantibody levels.
  • RozanolixizumabNeonatal Fc receptor blocker given by subcutaneous infusion.
  • AzathioprineConventional oral immunosuppressant used as a steroid-sparing agent.

Bottom line for clinicians

Livsayis is an option for adults with anti-AChR antibody-positive generalized myasthenia gravis who may be candidates for complement inhibition. It showed a clear benefit on MG-ADL over 24 weeks, with infrequent subcutaneous dosing as a potential convenience. Weigh the lack of head-to-head data against other targeted therapies, the limited follow-up, and the infection risk expected with C5 suppression.

Our coverage

We have not covered this drug yet.

Sources

  1. FDA list of novel approvals
  2. Vu T, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407:1712-1725.
  3. ClinicalTrials.gov NCT05070858
  4. Barratt J, et al. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2024;19:452-462.
  5. Badri P, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60:365-378.

Dosing, contraindications and full warnings are in the prescribing information.

New FDA approvals in your inbox

The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.

Your subscription opens securely in a new tab.

Last updated November 20, 2026 by 2 Minute Medicine.

For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.